Patients with obstructive sleep apnea syndrome (OSAS) are subject to an increased cardiovascular morbidity including systemic hypertension. Little is known about the effects of treatment with nasal continuous positive airway pressure (CPAP) on systemic hypertension. Methods: Automated ambulatory 24-h blood pressure (BP) monitoring was performed in 88 consecutive patients who were referred for evaluation of snoring or suspected OSAS. In addition, the long-term effects of CPAP therapy on 24-h BP were assessed. Results: A total of 62 patients had OSAS and 26 habitual snoring. Patients with OSAS had significantly higher mean arterial BP values than snorers (102.7 Ϯ 10.7 v 94.0 Ϯ 10.2 mm Hg; P Ͻ .01). Multiple stepwise linear regression analysis disclosed that the degree of systemic hypertension was independently associated with the severity of OSAS as determined by the apnea/hypopnea index (R ϭ 0.43; P Ͻ .001), but not with age, body mass index,
O
bstructive sleep apnea syndrome (OSAS) is a common health burden. It is estimated that 2% of women and 4% of men meet the minimal diagnostic criteria for this syndrome. 1 Patients with OSAS have decreased daytime performance, and they are also prone to an increased cardiovascular morbidity and mortality. 2, 3 Especially hypertension and OSAS are frequently associated: approximately one third of hypertensive patients have OSAS, 4 whereas about 50% of OSAS patients are hypertensive. 5 Although acute rises in blood pressure (BP) coinciding with obstructive apneas during sleep are well described, 6 the mechanisms responsible for systemic hypertension during the day are less well understood. Lately some debate has arisen about the cardiovascular consequences of OSAS and the relationship between OSAS and hypertension, 7 but recently published studies also suggest that there is an independent association between these two conditions. 8, 9 Nasal continuous positive airway pressure (CPAP) is a well established, widely used, and effective treatment of OSAS. 10 It has been shown that CPAP improves not only daytime function but also quality of life. 11 Furthermore, it seems to improve associated cardiovascular diseases such as pulmonary hypertension or left and right ventricular dysfunction. [12] [13] [14] Although several studies have shown a clear association between OSAS and high BP, 15, 16 the effects of OSAS treatment on hypertension have been less clearly defined, even though in small groups a blood pressure lowering effect of CPAP has been observed.
Therefore, the present study was designed to answer the following two questions: 1) Is there, besides the known association between OSAS and hypertension, a correlation between the severity of OSAS and the height of BP; and 2) are there predictors that allow one to estimate the potential BP lowering effect of CPAP therapy in essential hypertension?
For this purpose, we conducted a prospective study in patients with OSAS with and without systemic hypertension who were treated with CPAP.
Patients and Methods
A total of 91 consecutive patients referred to our sleep laboratory for snoring, suspected OSAS, or excessive daytime sleepiness between July and September 1999 were selected for the study. They were asked to agree to 24-h BP monitoring that would be performed in addition to polysomnography. No patient was receiving sedatives or muscle relaxants. There were no shift workers in our population. Of the 91 patients initially selected, one refused to participate, and in two BP measurement was not possible for technical reasons.
Those patients who had significant symptomatic OSAS (Epworth Sleepiness Scale Ն10) with an apnea/hypopnea index Ͼ10/h of sleep requiring CPAP therapy were also included in the prospective part of the study (see later here). Patients with craniofacial malformations or other conditions that make CPAP treatment impossible, those with cancer, and those who did not tolerate CPAP therapy, in whom CPAP was not effective, or in whom an insufficient compliance to follow-up was to be expected because of either distance or unreliability were excluded from the study. The study protocol was approved by the local ethics committee. Written informed consent was obtained from all patients before entry into the study.
Polysomnography
All patients underwent overnight polysomnography (Somnostar 4100, SensorMedics, Yorba Linda, CA) according to widely accepted methods. 19 It consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, submental and leg electromyography, and electrocardiography, and from noninvasive sensors for nasal and oral airflow, tracheal sounds (microphone), thoracic and abdominal respiratory movement (inductance plethysmography), and oxyhemoglobin level (Sat-Trak, finger-pulse oximeter, Sensor Medics, Yorba Linda, CA). The transducers and lead wires permitted normal positional changes during sleep. Bedtime and awakening time were at each subject's discretion. Polysomnography was terminated after final waking. The entire recording was supervised by a technician.
Polysomnography records were scored in 30-sec periods for sleep, breathing, and oxygenation. According to the commonly used clinical criteria, 19 a breathing event during objectively measured sleep was defined as abnormal if either a complete cessation of airflow lasting Ն10 sec took place (apnea) or a reduction in respiratory airflow of Ն50% of the tidal volume lasting Ͼ10 sec could be discerned (hypopnea). Obstructive apnea was defined as absence of tidal volume in the presence of paradoxical chest-wall motion. The average number of episodes of apnea and hypopnea per hour of sleep (apnea/hypopnea index) was calculated. When the apnea/hypopnea index was Ն10/h, associated with typical clinical features, OSAS was diagnosed. Sleep was staged manually using the methods of Rechtschaffen and Kales. 20 
Ambulatory Blood Pressure Recordings
All patients were asked about a history of systemic hypertension, medication use, and other medical conditions. On day 1 after hospital admission, ambulatory 24-h BP monitoring was performed in all patients (Custoscreen; Customed, Munich, Germany). The ambulatory BP monitor was validated using invasive BP measurements in our intensive care unit. Two BP cuffs of different sizes in relation to the upper arm circumference were selected. After attaching the arm cuff, three to four BP measurements were recorded simultaneously with manual measurements. The attachment was considered satisfactory if the difference between the automatic and the manual measurements was Յ5 mm Hg. During each recording, patients were asked to remain calm until the end of the measurement. Systolic, diastolic, and mean arterial BP values were determined by the oscillometric method with one measurement every 15 min during the daytime period (6 AM to 10 PM) and every 20 min during the nighttime period (10 PM to 6 AM). The exact time of BP recorded was determined randomly by the integrated computer software so that subjects could not anticipate cuff inflation. The recordings were made during the patients' usual activities. A detailed log was kept of the patients' activities during the recording. Patients with a 24-h mean arterial blood pressure Ն135 mm Hg (systolic) or Ն85 mm Hg (diastolic) were classified as hypertensive. 
Follow-Up
Patients with symptomatic OSAS treated with CPAP were followed for 9 months and then reevaluated by polysomnography and 24-h BP monitoring, using the same arm and cuff size for measurement. Compliance with prescribed CPAP therapy was based on the actual hours of CPAP usage as registered by an integrated hour meter. An attempt was made not to change the dose of antihypertensive medication during the study. Patient adherence to medication was evaluated using a structured questionnaire.
Statistical Analyses
Results are given as means Ϯ SD. All P values reported are two-tailed. Statistical analyses were performed with the computer software SPSS for Windows (SPSS, Chicago, IL). Intergroup differences were analyzed with Stu-dent t test for paired or unpaired samples as appropriate, with Bonferroni's correction for multiple comparisons. The association of OSAS with systemic hypertension was determined with 2 ϫ 2 contingency tables using Fisher's exact test.
The relationships between the 24-h values for mean BP values and specific risk factors were first explored by univariate regression analysis. To determine the independent association of CPAP therapy with the change of BP in the presence of other significant risk factors, stepwise multiple logistic regression analysis was performed in a second step. The multivariate statistical model was built in steps and was designed to select only those factors that correlated with the mean 24-h BP values at a level of significance of Յ.05 for the final multiple regression model.
Results
A total of 88 patients were included into the study. Of them, 62 had OSAS; the remaining 26 had habitual snoring without evidence of upper airway resistance syndrome or OSAS. Of the 88 patients, 28 were obese, with a body mass index of Ͼ30 kg/m 2 . Patients with OSAS and snorers did not differ with respect to body mass index and age; but, as expected, snorers had less respiratory events during sleep (Table 1) . Patients with OSAS had significantly higher mean arterial BP values as measured with a 24-h ambulatory monitor. In all, 46 of the patients with OSAS and 10 of the snorers had a known or newly diagnosed systemic hypertension, indicating a significantly higher prevalence in the OSAS group (P ϭ .001). Hypertension was previously undiagnosed in 27 patients with OSAS and in six snorers. Of the hypertensive patients, 22 were treated with antihypertensive agents (11 with angiotensin converting enzyme inhibitors, 14 with calcium channel blockers, two with a ␤-blocking agent); three patients also had coronary artery disease, which was treated with a nitrate in two patients. None of the patients had diabetes mellitus or chronic obstructive pulmonary disease.
To clarify whether a quantitative relationship existed between the severity of OSAS and the degree of hypertension, correlation analyses were performed. In the study group, there was a significant association between mean arterial BP and apnea/hypopnea index (r ϭ 0.39; P Ͻ .001) (Fig. 1A) , mean oxygen saturation during sleep (r ϭ Ϫ0.26; P Ͻ .02), and minimum oxygen saturation during sleep (r ϭ Ϫ0.38; P Ͻ .001) (Fig. 1B ), but not with age, body mass index, or smoking habits.
In addition, to find out whether the correlation between the severity of OSAS and the increase in BP was independent from influences of other variables, multiple stepwise linear regression analysis was performed, with mean arterial blood pressure as the dependent variable and indicators of the severity of OSAS, body mass index, age, and smoking habits as independent variables. The regression analysis disclosed that only the apnea/hypopnea index was independently associated with the degree of systemic hypertension (R ϭ 0.43; P Ͻ .001) ( Table 2) .
Follow-Up
To find out whether the antihypertensive effect of CPAP therapy can be predicted from clinical parameters, 52 patients (43 men, nine women) of those with OSAS were treated with CPAP and reevaluated after 9 months. Of these 52 patients, 37 had systemic hypertension. Of these, 13 were treated with antihypertensive agents (six with angiotensin converting enzyme inhibitors, six with calcium channel blockers [all dihydropyridine, no nondihydropyridine calcium channel blockers], one with a ␤-blocking agent); three patients also had coronary artery disease, which was treated with a nitrate in two patients. None of the patients had diabetes mellitus or chronic obstructive pulmonary disease.
All patients tolerated the treatment well, and none complained of excessive daytime sleepiness. The use of CPAP during the study period, as indicated by the hour meter, was 5.5 Ϯ 1.1 h/day (range 3.0 to 7.1). The mean CPAP pressure was 8.2 Ϯ 2.0 cm H 2 O (range 6 to 14). Body mass index did not change significantly during follow-up, and no patient changed his or her smoking behavior.
In all 52 patients, CPAP was still effective in treating OSAS (Table 3) . Medication was not changed during the study (with the exception of two patients in whom treatment with a calcium channel blocker was discontinued because of inadequate decrease in BP), and all patients strictly adhered to the prescribed medication. Of the 52 patients, 40 showed a decrease of mean arterial 24-h BP resulting in a significant change in the study group (Fig. 2,  Table 3 ).
To clarify the question of how far the improvement in nocturnal respiration is associated with an improvement in BP, correlation analyses were performed. The regression analysis disclosed that the change in mean arterial BP was not associated with the change of indicators of the severity of OSAS, CPAP compliance, body mass index, age, or smoking habits.
To find out predictors for those patients with systemic
FIG. 1. A and B) Mean arterial 24-h blood pressure (BP) plotted against apnea/hypopnea index (AHI), and minimum oxygen saturation during sleep (SaO 2 min). C and D)
Change of mean arterial 24-h BP plotted against pulse pressure at baseline, and mean heart rate during the day at baseline. hypertension whose BP improved with CPAP therapy, a subanalysis was performed. Bivariate and multiple stepwise linear regression analysis could demonstrate an independent association of the improvement of 24-h mean BP with the 24-h mean pulse pressure at baseline (r ϭ Ϫ0.36; P Ͻ .05) as well as the average heart rate during the day (r ϭ Ϫ0.35; P Ͻ 0.05) (Fig. 1, Table 4 ). None of the other possible risk factors tested (apnea/hypopnea index, minimum and mean nocturnal SaO 2 , body mass index, age, smoking) was included in the stepwise multiple logistic regression model because the significance level was Ͼ0.05. In a subgroup analysis of patients who were not taking antihypertensive medications, the significant correlation persisted between improvement of 24-h mean BP, both with the 24-h mean pulse pressure at baseline (r ϭ Ϫ0.48; P Ͻ .01) and the average heart rate during the day (r ϭ Ϫ 0.29; P Ͻ .05).
Discussion
These results document that there is a quantitative relationship between the severity of OSAS and the elevation Table 1 .
Values are given as means Ϯ SD. * Weight in kilograms divided by square of height in meters.
FIG. 2.
Mean arterial 24-h BP at baseline without and during follow-up with continuous positive airway pressure therapy. Other abbreviations as in Fig. 1 .
of BP in OSAS patients. Moreover, the severity of OSAS is a parameter affecting BP independently from other clinical characteristics. Under CPAP therapy, also normotensive patients experienced a decrease in BP. On the other hand, not all hypertensive OSAS patients showed a hypertensive response to CPAP. Compared with other studies on hypertension in OSAS patients, 17, 18 we examined a larger group of patients over a considerably longer period of time (9 months).
Hypertension and OSAS have many risk factors in common. This explains the controversy about a causal relationship, because confounding variables such as obesity (and its pattern of distribution), alcohol consumption, age, and levels of exercise make this link extremely hard to prove. 7 After adjusting for age, body mass index, and smoking habits we found an independent association between the severity of OSAS, as determined by the apnea/ hypopnea index, and the degree of hypertension. This quantitative relationship confirms findings of recently published population-based studies 9, 15, 16 and results obtained in an animal model. 8 How can the relationship between OSAS and hypertension be explained? It was shown that patients with OSAS have an increased sympathetic activity not only during the night but also during the day. 22 Furthermore, they have a higher norepinephrine-release rate to hypoxia than controls, 23 increased endothelin-1 levels, 24 and a reduced endothelium-dependent vascular relaxation. 25 In the therapy of OSAS, CPAP is widely used. 10 Despite extensive study, the hemodynamic short-term and especially long-term effects of CPAP have not been unequivocally clarified. Therapy with CPAP disrupts the vicious circle of interactions between sleep-disordered breathing and cardiac function: hypoxemia and hypercapnia as well as repetitive arousals from sleep are prevented, and sympathoadrenal tone decreases. 26 This might explain the beneficial effect of CPAP therapy on systemic hypertension in our study population: 40 of the 52 patients (both hypertensive and normotensive) showed a decrease in mean arterial 24-h BP, resulting in a significant change in the study group (from 103.7 Ϯ 10.4 to 99.1 Ϯ 10.8 mm Hg). In addition, antihypertensive medication could be discontinued in two of the patients. None of the other variables known to influence BP changed during the prospective follow-up period.
A control group was intentionally not included. This is an obvious shortcoming of the study design, but we had to use this approach to investigate long-term effects of CPAP on blood pressure: it would have been unethical either to withhold treatment of OSAS from symptomatic patients or to treat an unaffected control group with CPAP for 9 months without knowing about possible side effects. Moreover, no subject without OSAS and daytime sleepiness would have agreed to use CPAP for such a long time.
The only controlled study of the effects of CPAP on BP versus oral placebo examined 13 patients over a minimum of 3 weeks. 27 In this study, a BP decrease could be detected only in the subgroup of five patients who, while taking placebo, did not experience a decrease in BP during the night.
We used 24-h BP recordings because this monitoring offers the advantage of providing a more realistic setting for BP measurements, and it is more closely related to the target-organ damage associated with hypertension than clinical BPs. The results of our intervention study indicate that the association of OSAS with BP is not very close. This might explain why other clinical studies 28, 29 with small sample sizes or control groups of symptomatic patients who could be considered to have mild sleep-disordered breathing had negative findings.
We could not find a significant association between the degree of BP decrease with CPAP and polysomnographic parameters indicative of the degree of improvement of OSAS. This could be explained by the fact that hypertension, even if induced by OSAS, might subsequently be perpetuated by vascular remodeling or some secondary renal response to chronic preglomerular vasoconstriction and altered perfusion. Furthermore, OSAS is probably not the only cause of hypertension in these patients.
To identify predictors for those patients with systemic hypertension whose BP improved with CPAP therapy, a subanalysis was performed. The 24-h mean pulse pressure as well as the average heart rate during the day at baseline were associated with the improvement of 24-h mean BP. We can therefore speculate that OSAS patients with high pulse pressures or elevated heart rates at baseline (indicators of an increased sympathetic activity) are more likely to experience lower BP with treatment. However, this hypothesis needs to be confirmed in a prospective study with a larger sample size.
In conclusion, our study shows that CPAP therapy has a significant BP lowering effect in most, but not all, hypertensive patients with OSAS. Baseline heart rate and pulse pressure may be predictors of a beneficial effect of CPAP therapy on BP. Abbreviation as in Table 3 . * Multiple correlation coefficient.
